Completed PHASE1 INTERVENTIONAL 1-arm NCT01195311

A Dose-escalation Study in Subjects With Advanced Malignancies

A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies

Sponsor: Incyte Corporation

Conditions Solid Tumors and Hematologic Malignancy

Interventions INCB024360

Updated 7 times since 2017 Last updated: Jan 15, 2018 Started: Jul 31, 2010 Primary completion: May 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Solid Tumors and Hematologic Malignancy and is currently completed. Incyte Corporation leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2018 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Feb 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Incyte Corporation

Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States
• Philadelphia, United States